Sjögren's syndrome-like disease of C57BL/6.NOD-Aec1 Aec2 mice: Gender differences in keratoconjunctivitis sicca defined by a cross-over in the chromosome 3 Aec1 locus

Scandinavian Journal of Immunology

Volumn 64, Issue 3, 2006, Pages 295-307

  Nguyen, C ^a   Singson, E ^a   Kim, J Y ^a   Cornelius, J G ^a   Attia, R ^a   Doyle, M E ^a,b   Bulosan, M ^a   Cha, S ^a   Peck, A B ^a,b,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOSOME; BREEDING; CHROMOSOME 3; CHROMOSOME NOR; CONTROLLED STUDY; FEMALE; GENDER; GENE EXPRESSION PROFILING; GENE LOCUS; KERATOCONJUNCTIVITIS SICCA; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SJOEGREN SYNDROME; STOMATITIS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CROSSING OVER, GENETIC; DACRYOCYSTITIS; DISEASE MODELS, ANIMAL; FEMALE; KERATOCONJUNCTIVITIS SICCA; LACRIMAL APPARATUS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, INBRED STRAINS; MICE, TRANSGENIC; SEX CHARACTERISTICS; SIALADENITIS; SJOGREN'S SYNDROME; SUBMANDIBULAR GLAND;

EID: 33747075154     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2006.01828.x     Document Type: Article

References (61)

1. Fox RI, Kang HI. Pathogenesis of Sjogren's syndrome. Rheum Dis Clin North Am 1992;18:517-38.
2. Jonsson R, Dowman SJ, Gordon T. Sjögren's syndrome. In: Koopman W, ed. Arthritis and Allied Conditions - A Textbook in Rheumatology. Philadelphia, PA: Lippincott Williams & Wilkins, 2004:1681-705.
3. Arnett FC, Goldstein R, Duvic M, Reveille JD. Major histocompatibility complex genes in systemic lupus erythematosus, Sjogren's syndrome, and polymyositis. Am J Med 1988;85:38-41.
4. Anaya JM, Mantilla RD, Correa PA. Immunogenetics of primary Sjogren's syndrome in Colombians. Semin Arthritis Rheum 2005;34:735-43.
5. Nakken B, Jonsson R, Brokstad KA et al. Associations of MHC class II alleles in Norwegian primary Sjogren's syndrome patients: implications for development of autoantibodies to the Ro52 autoantigen. Scand J Immunol 2001;54:428-33.
6. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, Tochino Y. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu 1980;29:1-13.
7. Konttinen YT, Tensing EK, Laine M, Porola P, Tornwall J, Hukkanen M. Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sjogren's syndrome. J Rheumatol 2005;32:1071-5.
8. Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Perez Leiros C. Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. Clin Exp Immunol 2005;142:411-8.
9. Humphreys-Beher MG, Hu Y, Nakagawa Y, Wang PL, Purushotham KR. Utilization of the non-obese diabetic (NOD) mouse as an animal model for the study of secondary Sjogren's syndrome. Adv Exp Med Biol 1994;350:631-6.
10. Brayer J, Lowry J, Cha S et al. Alleles from chromosomes 1 and 3 of NOD mice combine to influence Sjogren's syndrome-like autoimmune exocrinopathy. J Rheumatol 2000;27:1896-904.
11. Brayer JB, Cha S, Nagashima H et al. IL-4-dependent effector phase in autoimmune exocrinopathy as defined by the NOD.IL-4-gene knockout mouse model of Sjogren's syndrome. Scand J Immunol 2001;54:133-40.
12. Cha S, Brayer J, Gao J et al. A dual role for interferon-gamma in the pathogenesis of Sjogren's syndrome-like autoimmune exocrinopathy in the nonobese diabetic mouse. Scand J Immunol 2004;60:552-65.
13. Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002;13:5-16.
14. Cha S, van Blockland SC, Versnel MA et al. Abnormal organogenesis in salivary gland development may initiate adult onset of autoimmune exocrinopathy. Exp Clin Immunogenet 2001;18:143-60.
15. Gao J, Cha S, Jonsson R, Opalko J, Peck AB. Detection of antitype 3 muscarinic acetylcholine receptor autoantibodies in the sera of Sjogren's syndrome patients by use of a transfected cell line assay. Arthritis Rheum 2004;50:2615-21.
16. Gao J, Killedar S, Cornelius JG, Nguyen C, Cha S, Peck AB. Sjogren's syndrome in the NOD mouse model is an interleukin-4 time-dependent, antibody isotype-specific autoimmune disease. J Autoimmun 2006;26:90-103.
17. Robinson CP, Brayer J, Yamachika S et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci USA 1998;95:7538-43.
18. Robinson CP, Cornelius J, Bounous DI, Yamamoto H, Humphreys-Beher MG, Peck AB. Infiltrating lymphocyte populations and cytokine production in the salivary and lacrimal glands of autoimmune NOD mice. Adv Exp Med Biol 1998;438:493-7.
19. Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-SCID mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996;79:50-59.
20. Robinson CP, Yamachika S, Bounous DI et al. A novel NOD-derived murine model of primary Sjogren's syndrome. Arthritis Rheum 1998;41:150-6.
21. Cha S, Nagashima H, Brown VB, Peck AB, Humphreys-Beher MG. Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background. Arthritis Rheum 2002;46:1390-8.
22. Hamano T, Mitsunaga S, Kotani S et al. Tear volume in relation to contact lens wear and age. CLAO J 1990;16:57-61.
23. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
24. Robinson CP, Bounous DI, Alford CE, Peck AB, Humphreys-Beher MG. Aberrant expression and potential function for parotid secretory protein (PSP) in the NOD (non-obese diabetic) mouse. Adv Exp Med Biol 1998;438:925-30.
25. Yui MA, Muralidharan K, Moreno-Altamirano B, Perrin G, Chestnut K, Wakeland EK. Production of congenic mouse strains carrying NOD-derived diabetogenic genetic intervals: an approach for the genetic dissection of complex traits. Mamm Genome 1996;7:331-4.
26. Chesnut K, She JX, Cheng I, Muralidharan K, Wakeland EK. Characterizations of candidate genes for IDD susceptibility from the diabetes-prone NOD mouse strain. Mamm Genome 1993;4:549-54.
27. Hill NJ, Lyons PA, Armitage N, Todd JA, Wicker LS, Peterson LB. NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans. Diabetes 2000;49:1744-7.
28. Robinson CP, Yamachika S, Alford CE et al. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjogren syndrome. Proc Natl Acad Sci USA 1997;94:5767-71.
29. Khovidhunkit W, Hachem JP, Medzihradszky KF et al. Parotid secretory protein is an HDL-associated protein with anticandidal activity. Am J Physiol Regul Integr Comp Physiol 2005;288:R1306-15.
30. Robinson CP, Bounous DI, Alford CE et al. PSP expression in murine lacrimal glands and function as a bacteria binding protein in exocrine secretions. Am J Physiol 1997;272:G863-71.
31. Pourmand N, Wahren-Herlenius M, Gunnarsson I et al. Ro/SSA and La/SSB specific IgA autoantibodies in serum of patients with Sjogren's syndrome and systemic lupus erythematosus. Ann Rheum Dis 1999;58:623-9.
32. Maran R, Dueymes M, Pennec YL, Casburn-Budd R, Shoenfeld Y, Youinou P. Predominance of IgG1 subclass of anti-Ro/SSA, but not anti-La/SSB antibodies in primary Sjogren's syndrome. J Autoimmun 1993;6:379-87.
33. Aparisi L, Farre A, Gomez-Cambronero L et al. Antibodies to carbonic anhydrase and IgG4 levels in idiopathic chronic pancreatitis: relevance for diagnosis of autoimmune pancreatitis. Gut 2005;54:703-9.
34. Harley JB, Alexander EL, Bias WB et al. Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjogren's syndrome. Arthritis Rheum 1986;29:196-206.
35. Cha S, Singson E, Cornelius J, Yagna JP, Knot HJ, Peck AB. Muscarinic acetylcholine type-3 receptor desensitization due to chronic exposure to Sjogren's syndrome-associated autoantibodies. J Rheumatol 2006;33:296-306.
36. Nguyen KH, Brayer J, Cha S et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice. Arthritis Rheum 2000;43:2297-306.
37. Garrett JR, Thulin A. Changes in parotid acinar cells accompanying salivary secretion in rats on sympathetic or parasympathetic nerve stimulation. Cell Tissue Res 1975;159:179-93.
38. Gaffen SL, Liu KD. Overview of interleukin-2 function, production and clinical applications. Cytokine 2004;28:109-23.
39. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003;74:961-5.
40. Dolcetti R, Boiocchi M. Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol 1996;14 (Suppl 14): S3-13.
41. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993;75:253-61.
42. Ishida Y, Nishi M, Taguchi O et al. Immune dysfunctions and activation of natural killer cells in human IL-2 and IL-2/IL-2 receptor L-chain transgenic mice. Cold Spring Harb Symp Quant Biol 1989;54 (Pt 2): 695-704.
43. Kahaleh MB, LeRoy EC. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989;110:446-50.
44. Tebib JG, Boughaba H, Letroublon MC et al. Serum IL-2 level in rheumatoid arthritis: correlation with joint destruction and disease progression. Eur Cytokine Netw 1991;2:239-43.
45. Milne CD, Paige CJ. IL-7: a key regulator of B lymphopoiesis. Semin Immunol 2006;18:20-30.
46. Hofmeister R, Khaled AR, Benbernou N, Rajnavolgyi E, Muegge K, Durum SK. Interleukin-7:physiological roles and mechanisms of action. Cytokine Growth Factor Rev 1999;10:41-60.
47. Lu L, Osmond DG. Apoptosis and its modulation during B lymphopoiesis in mouse bone marrow. Immunol Rev 2000;175:158-74.
48. Carvalho TL, Mota-Santos T, Cumano A, Demengeot J, Vieira P. Arrested B lymphopoiesis and persistence of activated B cells in adult interleukin 7()/)) mice. J Exp Med 2001;194:1141-50.
49. Grabstein KH, Waldschmidt TJ, Finkelman FD et al. Inhibition of murine B and T lymphopoiesis in vivo by an anti-interleukin 7 monoclonal antibody. J Exp Med 1993;178:257-64.
50. von Freeden-Jeffry U, Vieira P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine. J Exp Med 1995;181:1519-26.
51. Rich BE, Campos-Torres J, Tepper RI, Moreadith RW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J Exp Med 1993;177:305-16.
52. di Cesare, E, Previti, M, Lombardo, F, Mazzu, N, di Benedetto, A, Cucinotta D. Prevalence of autoantibodies to carbonic anhydrase II and lactoferrin in patients with type 1 diabetes. Ann N Y Acad Sci 2004;1037:131-2.
53. Alessandri C, Bombardieri M, Scrivo R et al. Anti-carbonic anhydrase II antibodies in systemic sclerosis: association with lung involvement. Autoimmunity 2003;36:85-9.
54. Gordon SC, Quattrociocchi-Longe TM, Khan BA et al. Antibodies to carbonic anhydrase in patients with immune cholangiopathies. Gastroenterology 1995;108:1802-9.
55. Kino-Ohsaki J, Nishimori I, Morita M et al. Serum antibodies to carbonic anhydrase I and II in patients with idiopathic chronic pancreatitis and Sjogren's syndrome. Gastroenterology 1996;110:1579-86.
56. Baum BJ, Dai Y, Hiramatsu Y, Horn VJ, Ambudkar IS. Signaling mechanisms that regulate saliva formation. Crit Rev Oral Biol Med 1993;4:379-84.
57. Masaki Y, Sugai S. Lymphoproliferative disorders in Sjogren's syndrome. Autoimmun Rev 2004;3:175-82.
58. Mucenski ML, Taylor BA, Ihle JN et al. Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 1988;8:301-8.
59. Liu Y, Chen L, Ko TC, Fields AP, Thompson EA. Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 2006;25:3565-75.
60. Yuasa H, Oike Y, Iwama A et al. Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 2005;24:1976-87.
61. Sullivan DA. Sex hormones and Sjogren's syndrome. J Rheumatol 1997;24:17-32.